BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1959 related articles for article (PubMed ID: 27332730)

  • 1. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
    Yaguchi T; Kawakami Y
    Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial Cancer Immunotherapies.
    Hellmann MD; Friedman CF; Wolchok JD
    Adv Immunol; 2016; 130():251-77. PubMed ID: 26923003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.
    Janakiram M; Pareek V; Cheng H; Narasimhulu DM; Zang X
    Immunotherapy; 2016 Jun; 8(7):809-19. PubMed ID: 27349980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
    Cheng F; Loscalzo J
    Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
    Wang Q; Wu X
    Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
    Sun L; Chen L; Li H
    Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
    Overwijk WW
    Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of immunotherapy for sarcomas.
    Miwa S; Nishida H; Tsuchiya H
    Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight into cancer immunotherapy.
    Escribese MM; Barber D
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():50-55. PubMed ID: 29108766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of cancers comes of age.
    Yousefi H; Yuan J; Keshavarz-Fathi M; Murphy JF; Rezaei N
    Expert Rev Clin Immunol; 2017 Oct; 13(10):1001-1015. PubMed ID: 28795649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adapting Cancer Immunotherapy Models for the Real World.
    Klevorn LE; Teague RM
    Trends Immunol; 2016 Jun; 37(6):354-363. PubMed ID: 27105824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
    Manieri NA; Chiang EY; Grogan JL
    Trends Immunol; 2017 Jan; 38(1):20-28. PubMed ID: 27793572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 98.